Thus, co-administration of febuxostat with other CYP2D6 substrates is not expected to require any dose adjustment for those compounds.
Seega ei ole eelduste kohaselt vaja febuksostaadi manustamisel koos teiste CYP2D6 substraatidega nende ühendite annuseid kohandada.